S&P Global Ratings recognizes Biocon Biologics’ accelerated debt reduction

 11-Dec-2025

Biosimilars are reimagining the future of healthcare access

 26-Nov-2025

Biocon shares gain 2% as Japan partner launches Ustekinumab biosimilar

 21-May-2025

5 products to be launched in 18 mths, US insulin mkt share up: BBL MD & CEO

 19-May-2025

Yesintek Biosimilar Shows Comparable Efficacy, Lower Immunogenicity Than Stelara, Says Elena Wolff-Holz, MD

 11-May-2025

Biocon bullish on US market share with over 70% payer access

 11-May-2025

Biocon Q4 Profit Surges 2x to Rs 344 Cr

 08-May-2025

Biocon Q4 Results: Net profit more than doubles YoY, beats estimates; declares final dividend

 08-May-2025

Biocon Q4 net profit surges 153%, biosimilars, generics drive growth

 08-May-2025

Biocon Q4 results: Net profit surges 153% at Rs 344 crore

 08-May-2025

Biocon edges higher after biologics arm secures multiple market access deals for Yesintek

 05-May-2025

Biocon Biologics secures multiple market access agreements in US for Yesintek

 05-May-2025

Biocon Biologics Secures Strong Market Access Coverage for Yesintek™ in the United States Covering 100+ Million Lives

 05-May-2025

Biocon Biologics secures multiple market access agreements in US for Yesintek

 05-May-2025

As Novo Nordisk scales back, Eris and Biocon Biologics hit the sweet spot in India’s insulin market

 29-Apr-2025

Biocon shares up 2% on positive opinions for biosimilar Denosumab in Europe

 28-Apr-2025

Biocon Biologics receives positive opinion for biosimilar Denosumab in Europe

 28-Apr-2025

Johor to become Asia’s largest insulin hub with Biocon’s RM2.7B investment; expansion to create over 300 high-skilled jobs

 19-Mar-2025

Leadership Lessons from Kiran Mazumdar-Shaw: A Pioneer in India’s Biotech Journey

 19-Mar-2025

Johor to become Asia’s biggest insulin hub, with Biocon’s RM1.1bil investment boost

 18-Mar-2025

Promising Results for Ustekinumab, Adalimumab Biosimilars Presented at AAD

 18-Mar-2025

Biosimilar drugs, why the future is played out in India

 11-Mar-2025

Biocon Biologics Agrees to Supply Civica With Materials to Bring Another Biosimilar Insulin Aspart to Market

 10-Mar-2025

Biocon Biologics and Civica, Inc. Collaborate to Expand Insulin Aspart Access in the United States

 7-Mar-2025

Biocon’s Ustekinumab biosimilar gets marketing authorisation for EU region

 18-Feb-2025

Biocon’s growth formula: Generics & biosimilars

 11-Feb-2025

Biocon betting big on new product launches for growth

 11-Feb-2025

Biocon Biologics investors are more confident after revenue growth: Mittal

 01-Feb-2025

Biocon Biologics sees insulin demand growing across markets, says CEO Tambe

 31-Jan-2025

Biocon’s S&P Global ESG score improves to 69 for 2024

 27-Jan-2025

Biocon Biologics’ biosimilar for psoriasis and arthritis recommended for approval in Europe

16-Dec-2024

Jamsetji Tata awarded to Kiran Mazumdar-Shaw

15-Dec-2024

Biocon Biologics recognized as Asia IP Elite for 2024 by Intellectual Asset Management

11-Dec-2024

Biocon Biologics gets US nod to launch Stelara biosimilar

 01-Dec-2024

There is need for tech-driven approaches to biology: Kiran Mazumdar-Shaw

20-Nov-2024

Bioengineering is really the way we have to move forward: Mazumdar-Shaw

19-Nov-2024

‘We will continue to explore options to further reduce debt in the near term’

12-Nov-2024

Will launch 3 biosimilars globally in 2-3 years: Biocon Biologics CEO & MD

05-Nov-2024

Biocon Biologics Confident Of Tackling Pricing Pressures, Ready To Compete

05-Nov-2024

A Conversation with Joshua Salsi, Head of North America, Biocon Biologics

04-Nov-2024

Biocon Biologics Announces Results of Aflibercept Switching Study at American Academy of Ophthalmology Annual Meeting

 24-Oct-2024

Kiran Mazumdar-Shaw Honored with Doctor of Science Degree by Concordia University for Pioneering Contributions to Biotechnology

 18-Oct-2024

Need to strengthen national policies to increase access and adoption of biosimilars, reveals new report

 08-Oct-2024

‘Quiet Giant’ Biocon Sets Out Vision For Biosimilars

 07-Oct-2024

With refinancing done, focus will now be on debt reduction: Biocon Biologics CFO

 04-Oct-2024

Biocon Biologics Adalimumab and Ustekinumab Biosimilars Meet Phase 3 Trial Objectives

 26-Sep-2024

Biology opens up new frontiers in medicine to cure genetic diseases: Kiran Mazumdar Shaw

 14-Sep-2024

Biocon Biologics Inks Pact with JJ and Janssen Arms to Market ‘Bmab’ in Europe and Japan

 29-Aug-2024

Kiran Mazumdar-Shaw: Spearheading pharma innovation

 26-Aug-2024

Local clinical trial waiver will accelerate access to lifesaving drugs: Kiran Mazumdar-Shaw

 21-Aug-2024

Excited about gain in market share in US, says Biocon chief Kiran Mazumdar Shaw

 25-June-2024

EMA approves Biocon Biologics’ new monoclonal antibodies facility, renews GMP certifications for India and Malaysia sites

 24-June-2024

Biocon Biologics gets EMA nod to manufacture biosimilar Bevacizumab at its new facility in Bengaluru

 24-June-2024

Aim is to be among top three biosimilars players globally: Biocon Biologics CEO Shreehas Tambe

 27-May-2024

Acceleration of biosimilar business, debt reduction to be key priorities in FY25: Biocon Chief

 18-May-2024

Biocon’s Biosimilar Business Set For Strong Growth: CEO Shreehas Tambe

 18-May-2024

Biocon Biologics Signs 10-Year Deal With Eris Lifesciences To Expand Patient Access

 14-Mar-2024

Biocon Biologics: US Biosimilars Are A Marathon, Not A Sprint

 13-Mar-2024

Biocon Biologics Secures US Entry Date For Bmab 1200, A Stelara Biosimilar

 01-Mar-2024

Biocon included in S&P Global Sustainability Yearbook 2024

 20-Feb-2024

Biocon Biologics focusing on market share gains of biosimilars in key markets

 13-Feb-2024

We are focused on consolidating our acquired businesses for the coming fiscal year: Biocon Biologics

 12-Feb-2024

Biocon Biologics inks pact with Sandoz for sale of 2 biosimilar products in Australia

 09-Feb-2024

Budget ’24 | A vision of ‘Viksit Bharat’, driven by inclusion and innovation: Kiran Mazumdar Shaw

 02-Feb-2024

Biocon to commercialize biosimilars in 31 European countries

 22-Dec-2023

Biocon Biologics grants Sandoz exclusive rights to market biosimilar adalimumab in Japan

 22-Dec-2023

Biocon Biologics completes integration of Viatris’ biosimilars business

 18-Dec-2023

Biocon Biologics Clinches Seventh Consecutive Asia IP Elite Recognition

 15-Dec-2023

Taking Control Of Our Destiny: Biocon Biologics CEO Tambe Celebrates European Viatris Integration

 07-Dec-2023

Biocon Biologics integrates Viatris’ biosimilar biz in 31 European nations

 30-Nov-2023

Interview With Shreehas Tambe, MD On Biocon’s Strong Q2 Earnings And Acquisition Plans

 15-Nov-2023

Biocon Biologics targets top three biosimilar spot: Shreehas Tambe

 13-Nov-2023

Biocon Biologics receives UK regulator’s approval for ophthalmic drug YESAFILI

 13-Nov-2023

Biocon Biologics to sell 2 non-core branded formulations businesses to Eris Lifesciences for ₹366 cr

 08-Nov-2023

Kedar Upadhye steps in as new CFO of Biocon Biologics

 19-Oct-2023

Biocon Biologics integrates Viatris Biosimilars in North America, shares up

 07-Sep-2023

Biocon Biologics announces top leadership appointments

 04-Aug-2023

Biocon Biologics completes integration of biosimilars business in 70+ emerging markets

 05-July-2023

Biocon Biologics Ltd launches biosimilar HULIO in US

 05-July-2023

Biocon Biologics Ltd launches biosimilar HULIO in US

 05-July-2023

SAT quashes insider trading charges against Biocon Biologics Deputy CEO

05-Aug-2022

SAT quashes insider trading charges against Biocon official Shreehas Tambe

04-Aug-2022

Biocon Biologics Receives EU Good Manufacturing Practice Certification

10-July-2022

Biocon Biologics’ antibody drug unit in Bengaluru gets EU GMP certificate

06-July-2022

Biocon Biologics receives EU GMP certification for its new biologics manufacturing facility in Bengaluru

 05-July-2022

Biocon Biologics expects big gains from integration of Viatris business, SII deal

 09-June-2022

Expect regulatory nods for deal with Serum and Viatris to come by H2: Kiran Mazumdar-Shaw, chairperson, Biocon and Biocon Biologics

04-May-2022

Biocon Biologics may close $3.34 billion Viatris deal in Q1

02-May-2022

Eyeing over 15% market share in US for insulin Glargine: Shreehas Tambe

30-April-2022

Biocon Biologics expects R&D expenses to hover between 10-15% in the next financial year

29-April-2022

Biocon Biologics acquires Viatris for $3.33 billion

01-Mar-2022

Biocon Biologics acquires Viatris’ biosimilars business in $3.3 bn deal

28-Feb-2022

R&D expenditure will rise in the coming quarters: Biocon Biologics MD

25-Jan-2022

Insulins access program for young expanded in Dec quarter: Biocon Biologics MD

24-Jan-2022

Biocon Biologics set to reap biosimilar insulin glargine opportunity in US

22-Jan-2022

The Medicine Box: Kiran Mazumdar-Shaw on biosimilar interchangeable status for Biocon’s diabetes drug

25-Nov-2021

Biocon Biologics, Viatris confirm offering steep savings on long-acting insulin through Walgreens Prescription Savings Club

19-Nov-2021

Walgreens to sell Biocon’s insulin Semglee in the U.S.

19-Nov-2021

Biocon Biologics, Viatris launch interchangeable insulin biosimilar for US

 16-Nov-2021

Biocon Rating: Hold – Vaccines to complement biosimilar portfolio

 20-Sep-2021

Biocon Biologics, Serum Institute Life Sciences announce strategic alliance

 20-Sep-2021

Interchangeable insulin to help us compete with big insulin makers: Kiran Mazumdar-Shaw

 29-Aug-2021

Shreehas Tambe named Deputy CEO of Biocon Biologics

 02-Mar-2021

Biocon Biologics, Viatris get CHMP nod for Abevmy

 02-Mar-2021

Biocon Biologics to partner with International Diabetes Federation

 16-Feb-2021

Biocon Biologics Receives USD 150 Million Capital Injection from Goldman Sachs

08-Nov-2020

India-based company brings affordable insulin to 2 PH towns

23-Oct-2020

India’s Biocon secures approval to use drug on coronavirus patients

 11-July-2020

Biosimilar drugs can help us reach $1 billion target soon

16-Jun-2020

Kiran Mazumdar-Shaw named EY World Entrepreneur of 2020

 06-Jun-2020

Covid provides larger opportunity to shape the biosimilar landscape

 19-May-2020

Biocon’s cancer biosimilar gets US FDA acceptance for review

 10-Mar-2020

Biocon chief is EY entrepreneur for 2019

 22-Feb-2020

Biocon Biologics Eyes $200M. Plans IPO in 2 Yrs: Mazumdar-Shaw

 27-Jan-2020

Biocon, partner Mylan launch oncology biosimilar trastuzumab in US

11-Dec-2019

Biocon, Mylan get nod for pegfilgrastim drug

28-Nov-2019

Indian company makes it to top 10 best employers in biotech category

30-Oct-2019

Insulin at ₹7 will be a gamechanger for us

26-Oct-2019

Life-enabling product like insulin should be made affordable: Shaw

28-Sep-2019

Biocon plans to halve insulin prices

27-Sep-2019

Biocon sets $1 billion target for biologics business

25-Oct-2019

Biocon subsidiary acquires Pfizer’s R&D facility in Chennai

25-Sep-2019

Ramp-up of biosimilar portfolio to boost Biocon

22-Aug-2019

Our aim is to be a global leader in biosimilars biz: Biocon Biologics CEO

 30-Jul-2019

Biosimilars, research key drivers for Biocon

 18-Jun-2019

Trastuzumab’s US launch will be a big opportunity for Biocon-Mylan: Shaw

 18-Jun-2019

Biocon’s Bengaluru biologics units get European agency nod

 15-Jun-2019

The First Lady of Biotech

 08-Jun-2019

Canada clears Mylan & Biocon’s Biosimilar

 23-May-2019

Biocon drug gets commercial rights to global markets

 09-May-2019

Biosimilars to help Biocon hit $1bn revenue in FY20

 30-Apr-2019

Kiran Mazumdar-Shaw conferred with honorary doctorate from Deakin University, Australia

 18-Apr-2019

Research must be promoted in colleges

 08-Apr-2019

ET Prime celebrates Women’s Excellence in Business & Innovation

 05-Apr-2019

Breakthrough innovation is taking place but we’re not leveraging it

 05-Apr-2019

Kiran Mazumdar-Shaw conferred with Honorary Doctorate

 04-Apr-2019

Biocon Biologics India appoints Dr. Christiane Hamacher as CEO

 01-Apr-2019

Biocon chief stresses on gender equality

 29-Mar-2019

Kiran back as Infy’s independent director

 19-Mar-2019

Govt Should Scale Up Philanthropic Capital

 18-Mar-2019

Cost of select insulin increases up to 20%

 15-Mar-2019

Role of Indian women in Science & Technology

 12-Mar-2019

The growing share of biosimilars revenue is doing wonders for our business

 11-Mar-2019

Biosimilars offer a huge opportunity for Biocon

 08-Mar-2019

Future jobs will be different: Shaw

 07-Mar-2019

Pharma specialist new CEO of Biocon Biologics

 03-Mar-2019

Hamacher is CEO of Biocon Biologics

 02-Mar-2019

In bid to curb profiteering, govt caps margins of 42 cancer drugs

 28-Feb-2019

Shortage of women for leadership roles

 23-Feb-2019

Biocon’s Trastuzumab receives approvals in EU

 13-Feb-2019

Kiran Mazumdar-Shaw elected member of US-based NAE

 09-Feb-2019

Biosimilars make Biocon stand apart

 28-Jan-2019